{
    "clinical_study": {
        "@rank": "141303", 
        "arm_group": [
            {
                "arm_group_label": "iron chelation", 
                "arm_group_type": "Active Comparator", 
                "description": "Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will continue their chelation therapy."
            }, 
            {
                "arm_group_label": "blood transfusion only", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will be subjected to discontinuation of their chelation therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "safety and  efficacy of different iron chelation therapy in transfusion dependent\n      beta-thalaasemia patients with low serum ferritin and continued regular transfusion regimen."
        }, 
        "brief_title": "Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Beta-thalassemia", 
            "Serum Ferritin", 
            "Iron Chelation Therapy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Beta-Thalassemia", 
                "Thalassemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Treatment of transfusional iron overload in TM patients with low serum ferritin (continued\n      decrease in serum ferritin ) even after reduction of chelation dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Subjects with low transfusional iron overload secondary to thalassemia major\n             showing downward-trend in SF over last 6 months ( 2 readings are needed).\n\n               -  Thalassemia major patients with SF equal or less than 500 after reduction of\n                  chelation dose. Patients on different types of chelation monotherapy will be\n                  included\n\n               -  The subjects must also have a level of understanding and willingness to\n                  cooperate with the confinement and procedures described in the consent form and\n                  scheduled by the study site. In addition, he/she must be able to provide\n                  voluntary written informed assent or consent forms.\n\n        Exclusion Criteria:\n\n          -  subjects with HIV positive or have active HCV.\n\n          -  A history of serious immunologic hypersensitivity to any medication such as\n             anaphylaxis or angioedema.\n\n          -  Participation in a previous investigational drug study within the 30 days preceding\n             screening.\n\n          -  A woman of childbearing potential must have a negative serum pregnancy test at\n             screening. She must use a medically acceptable form of birth control during the study\n             and for a month afterwards who are pregnant or breast-feeding.\n\n          -  An inability to adhere to the designated procedures and restrictions of this\n             protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996683", 
            "org_study_id": "iron chelation in thalassemia"
        }, 
        "intervention": {
            "arm_group_label": [
                "iron chelation", 
                "blood transfusion only"
            ], 
            "description": "Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving \"normal\" body iron stores in poly-transfued arm1.\nArm 2 will only recieve blood transfusion with no chelation", 
            "intervention_name": "desferal, ferriprox, blood transfusion", 
            "intervention_type": "Drug", 
            "other_name": [
                "deferiprone", 
                "deferoxamine"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Deferoxamine", 
                "Deferiprone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "B-thalassemia", 
            "ferritin"
        ], 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "Pediatric Hematology clinic, Ain Shams University"
            }, 
            "investigator": [
                {
                    "last_name": "Mohsen S Elalfy, professor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Amira A Adly, Assist. prof.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yasmine I Elhenawy, lecturer", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Prospective Comparative Study of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)", 
        "overall_contact": {
            "email": "amiradiabetes@yahoo.com", 
            "last_name": "Amira A M Adly, Asst. prof", 
            "phone": "01005245837"
        }, 
        "overall_contact_backup": {
            "email": "dr_yasmi@yahoo.com", 
            "last_name": "Yasmine I Elhenawy, lecturer", 
            "phone": "01004084038"
        }, 
        "overall_official": {
            "affiliation": "Ain Shams University", 
            "last_name": "Mohsen S. Elalfy, professour", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "non inferiority of discounting  chelation compared with continuing chelation in thalassemia patients  with low serum ferritin and/or showing a downward-trend of SF(serum ferritin) over previous 6 months after reduction of chelation dose with continuation of regular transfusion regimen.", 
            "measure": "downward-trend of SF(serum ferritin) over previous 6 months after reduction of chelation dose with continuation of regular transfusion regimen.", 
            "safety_issue": "Yes", 
            "time_frame": "6 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996683"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ain Shams University", 
            "investigator_full_name": "Mohsen Saleh Elalfy", 
            "investigator_title": "professor of pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "determine the safety and occurrence of AEs in both studied groups (with and without chelation) in relation to different chelation therapy.", 
            "measure": "safety and occurrence of AEs in both studied groups (with and without chelation) in relation to different chelation therapy.", 
            "safety_issue": "Yes", 
            "time_frame": "12 month"
        }, 
        "source": "Ain Shams University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ain Shams University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}